Paclitaxel, Ifosfamide, and Cisplatin in Patients with Poor-prognosis Disseminated Nonseminomatous Germ Cell Tumors with Unfavorable Serum Tumor Marker Decline After First Cycle of Chemotherapy. The GCT-SK-003 Phase II Trial
Open Access
- 22 September 2021
- journal article
- research article
- Published by Elsevier BV in European Urology Open Science
- Vol. 33, 19-27
- https://doi.org/10.1016/j.euros.2021.09.002
Abstract
No abstract availableFunding Information
- Vedecká Grantová Agentúra MŠVVaŠ SR a SAV
- Ministerio de Sanidad, Consumo y Bienestar Social (2018/39-LFUK-13)
- Agentúra na Podporu Výskumu a Vývoja (APVV-15-0086)
This publication has 36 references indexed in Scilit:
- Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell TumorsJournal of Clinical Oncology, 2016
- Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trialThe Lancet Oncology, 2014
- A Randomised Phase 2 Trial of Intensive Induction Chemotherapy (CBOP/BEP) and Standard BEP in Poor-prognosis Germ Cell Tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604)European Urology, 2014
- A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974)Annals of Oncology, 2011
- Randomized Trial Comparing Bleomycin/Etoposide/Cisplatin With Alternating Cisplatin/Cyclophosphamide/Doxorubicin and Vinblastine/Bleomycin Regimens of Chemotherapy for Patients With Intermediate- and Poor-Risk Metastatic Nonseminomatous Germ Cell Tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MPJournal of Clinical Oncology, 2008
- Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international studyAnnals of Oncology, 2007
- Phase III Randomized Trial of Conventional-Dose Chemotherapy With or Without High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Rescue As First-Line Treatment for Patients With Poor-Prognosis Metastatic Germ Cell TumorsJournal of Clinical Oncology, 2007
- Combination of Paclitaxel, Ifosfamide, and Cisplatin Is an Effective Second-Line Therapy for Patients With Relapsed Testicular Germ Cell TumorsJournal of Clinical Oncology, 2005
- Early Predicted Time to Normalization of Tumor Markers Predicts Outcome in Poor-Prognosis Nonseminomatous Germ Cell TumorsJournal of Clinical Oncology, 2004
- Treatment of Disseminated Germ-Cell Tumors with Cisplatin, Bleomycin, and either Vinblastine or EtoposideThe New England Journal of Medicine, 1987